3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
3
Unknown
2
Recruiting
2
Withdrawn
1
Not yet recruiting
1
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Prostatic Neoplasms
3
Neoplasms
3
Leukemia, Myeloid, Acute
3
Breast Neoplasms
3
Pancreatic Neoplasms
2
Neoplastic Cells, Circulating
2
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Myeloid
1
Rectal Neoplasms
1
Pruritus
1
Polycystic Ovary Syndrome
1
Papillomavirus Infections
1
Pancreatic Adenocarcinoma
1
Overweight
1
Oropharyngeal Neoplasms
1
Opioid-Related Disorders
1
Obesity
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Follicular
1
Liver Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Cyclophosphamide
8
Azacitidine
8
fludarabine phosphate
6
fludarabine
6
Peripheral Blood Stem Cell Transplantation
6
Whole-Body Irradiation
5
Methotrexate
5
Cyclosporine
5
Busulfan
5
Decitabine
4
Tacrolimus
3
Mycophenolic Acid
3
Filgrastim
3
Cytarabine
3
AP 1903 reagent
3
venetoclax
2
magrolimab
2
Stem Cell Transplantation
2
Specimen Handling
2
Sirolimus
2
Saline Solution
2
Radiotherapy
2
Nivolumab
2
Cyclosporins
2
Biopsy
2
Alemtuzumab
2
tumor-cells apoptosis factor, human
1
sabatolimab
1
ponatinib
1
plerixafor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Myelodysplastic Syndromes
×
Blood Specimen Collection
×
Clear all
NCT04953312
2026-03-12
CALPRO
Assistance Publique - Hôpitaux de Paris
Phase NA
Withdrawn